"Glatiramer Acetate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068717
|
| MeSH Number(s) |
D12.644.219
|
| Concept/Terms |
TV 5010- TV 5010
- 5010, TV
- TV5010
- TV-5010
|
Below are MeSH descriptors whose meaning is more general than "Glatiramer Acetate".
Below are MeSH descriptors whose meaning is more specific than "Glatiramer Acetate".
This graph shows the total number of publications written about "Glatiramer Acetate" by people in this website by year, and whether "Glatiramer Acetate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glatiramer Acetate" by people in Profiles.
-
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate. Ann Hematol. 2022 08; 101(8):1885-1886.
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
-
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
-
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease. PLoS One. 2013; 8(6):e66772.
-
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013 Dec; 113(4):415-20.
-
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
-
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature review. Clin Breast Cancer. 2008 Oct; 8(5):449-52.
-
Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production. Autoimmunity. 2008 Aug; 41(5):363-71.
-
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.
-
Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003 Apr; 137(1-2):144-53.